Effectiveness of Bupropion for Smokers Recovering From Alcohol Dependence

Phase 3

Completed

Conditions: Alcohol-Related Disorders
Smoking Cessation

Interventions: Drug: placebo
Drug: Bupropion

Registration Number: NCT00304707

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Brief Summary: Smoking is often a problem for alcohol dependent individuals. Many people who seek treatment for alcohol dependence are unable to quit smoking. The purpose of this study is to evaluate the effectiveness of bupropion, an antidepressant medication, in treating smokers receiving treatment for alcohol dependence.

Detailed Description: Past research suggests that over 75% of alcohol dependent individuals in early alcohol recovery smoke cigarettes; smoking-related mortality exceeds alcohol-related mortality in this population. Many alcohol dependent individuals in early recovery are interested in smoking cessation treatment; however, studies indicate that these smokers find it very difficult to quit smoking. More effective treatment methods are needed for smokers in early alcohol recovery. Bupropion is a dopaminergic antidepressant that may be effective in treating nicotine dependent individuals. The purpose of this study is to evaluate the effectiveness of bupropion in nicotine dependent individuals receiving treatment for alcohol dependence. In addition, this study will investigate the psychological mechanisms that may mediate the efficacy of bupropion in smoking cessation. We will also collect DNA from subjects in order to explore whether response to bupropion is mediated by particular genetic variants in the dopaminergic, metabolic and nicotinic receptor systems of smokers.

Participants will be randomly assigned to receive either 300 mg of bupropion or placebo, daily for 8 weeks. In addition, all participants will receive a nicotine patch for 7 weeks. This will consist of a 21-mg nicotine patch for 4 weeks, a 14-mg nicotine patch for 2 weeks, and a 7-mg nicotine patch for 1 week. All participants will undergo seven counseling sessions. Follow-up visits will occur at Weeks 7, 12, and 24. Pre-quit variables (e.g., smoking satisfaction) and three post-quit variables (craving, nicotine withdrawal, and negative effects) will be evaluated at all study visits.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 143

Inclusion Criteria

Smokes a minimum of 10 cigarettes daily for at least 1 year prior to study entry
Abstinence from alcohol and other non-nicotine drugs for between 1 and 12 months at time of study entry
Meets criteria for alcohol dependence or abuse in the 12 months prior to study entry

Exclusion Criteria

History of seizures, head trauma and/or severe hepatic cirrhosis
Current use of medications known to affect smoking behavior and/or cessation
Use of tricyclic antidepressant medication and monoamine oxidase inhibitors
Major depressive disorder within the month prior to study entry
Eating disorder within the year prior to study entry
History of bipolar or psychotic disorder
Pregnant or breastfeeding
Unstable serious medical disorder
History of migraines
Currently using smokeless tobacco, pipes, or cigars

Study & Design

Study Type: INTERVENTIONAL

Study Design: FACTORIAL

Arm && Interventions

Group	Intervention	Description
1	placebo	placebo
2	Bupropion	participants in this arm receive bupropion

Primary Outcome Measures

Name	Time	Method
Smoking Abstinence	week 7, week 11 and week 24 after scheduled quit day	The number of subjects in each treatment group who were smoking abstinent (7-day point prevalence) at week 7 (end of treatment), week 11 and week 24.

Secondary Outcome Measures